Respira has invented a revolutionary inhalation device and accompanying liquid formulation capable of delivering inhalable nicotine with similar pharmacokinetics as a cigarette or vaporizer – with none of the harmful or potentially harmful constituents (HPHCs).
Respira is currently pursuing a 505(b)(2) authorization for the world’s first inhalable Nicotine Replacement Therapy (NRT). In light of the devastating effects of the vaping epidemic, resulting in nicotine addiction in 25-33% of US high schoolers, there has never been a more critical time to offer nicotine users a safe and effective pathway to kick the habit, which happens to be the number one cause of preventable death in both the US and the world.
Importantly, Respira is a platform device and biotechnology company pioneering what we consider the evolution of the hypodermic needle, with nicotine just the first of numerous active pharmaceutical ingredients identified for development.
BlueLedge is proud to have been lead on Respira’s bridge rounds leading up to their Series A in 2020 and 2021.
Mission Barns has developed a scalable system for producing real animal fat cells for incorporation in plant-based foods – enabling plant-based foods that meat eaters actually want to eat. Importantly, Mission Barns can tailor the fatty acid profile of their fat cells to represent the pinnacle of nutrition science while nonetheless tasting identical to the fats we have evolved to love, like lard, tallow, and schmaltz.
BlueLedge is proud to have been the largest investor in Mission Barns $24m Series A in 2021.
Exogenesis has developed a novel form of particle acceleration enabling their Accelerated Neutral Atom Beam (ANAB) technology. Unlike legacy technologies such as plasma, ANAB is capable of ultra-shallow surface processing with highly collimated neutral particles. Whereas legacy systems rely on charged particles that repel each other and spread out chaotically similar to a shotgun, ANAB behaves more like a rifle and thereby enables unprecedented precision in surface modification.
While applications of ANAB are diverse, the first to be formally commercialized is as a source of surface energy modification via nanometer scale texturization of biomedical devices. ANAB treated devices like those sold by nanoMesh (a subsidiary) have bioactive surfaces that dramatically reduce the risk of infection while promoting seamless integration in the human body.
BlueLedge is proud to have led a bridge investment in 2021.
Grolltex has developed a patented method of producing the highest quality graphene in the world at costs orders of magnitude lower than industry incumbents. First synthesized in 2010, single layer graphene is a ‘wonder material’ poised to revolutionize countless industries from diagnostics, advanced electronics, and membranes.
Grolltex is currently developing a revolutionary biosensor by functionalizing a bioFET built on its graphene with peptide nucleic acids (PNAs). The result promises to be an agnostic biosensor capable of testing for any complimentary genetic sequence… all at an unprecedentedly low cost.
BlueLedge is proud to have led Grolltex’s Series A in 2021.